Identification of plant-derived natural products as potential inhibitors of the  proteasome by unknown
Zheng et al. BMC Complementary and Alternative Medicine 2014, 14:400
http://www.biomedcentral.com/1472-6882/14/400RESEARCH ARTICLE Open AccessIdentification of plant-derived natural products as
potential inhibitors of the Mycobacterium
tuberculosis proteasome
Yuejuan Zheng1, Xin Jiang1*, Feng Gao2, Junxiang Song1, Jinxia Sun1, Lixin Wang1, Xiaoxia Sun1, Zhenhui Lu3
and Huiyong Zhang3Abstract
Background: The Mycobacterium tuberculosis (Mtb) proteasome has been established as a viable target for the
development of anti-tuberculosis agents. In this study, the inhibitory activities of 100 plant-derived natural products
on the Mtb proteasome were analyzed to identify novel potential inhibitors.
Methods: The fluorescent substrate Suc-Leu-Leu-Val-Tyr-AMC can be hydrolyzed by the proteasome to release free
AMC, the fluorescence of which is proportional to the proteasome activity. The inhibitory activities of 100 natural
products (each at a final concentration of 200 μM) were detected by this method using MG132 as a positive control.
Results: Twelve of these natural products (10 of which were flavonoids) inhibited the activity of the Mtb proteasome
by more than 65%. Comparison of the structural differences between the flavonoids with good inhibitory activity and
those without inhibitory activity revealed that the hydroxyl at the flavonoid C ring C-3 or the hydroxyl/methoxyl at the
flavonoid A ring C-6 were critical for the inhibition of proteasomal activity.
Conclusions: These data indicate that flavonoids represent a basis for rational structural design in the process of novel
anti-tuberculosis drug discovery.
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Mycobacterium tuberculosis (Mtb) remains an important
global pathogen that is considered to have infected one-
third of the world’s population, causing the death of 1.3
million people, with 8.6 million new and relapsed infec-
tions in 2012 (World Health Organization Tuberculosis
Data and Statistics, 2013) [1]. The development of new
drugs is critical for the future control of tuberculosis
(TB) and a number of promising compounds are cur-
rently in the pipeline at various stages of drug discovery
and clinical development [2,3]. New TB drugs are re-
quired to be active against both replicating and nonrepli-
cating bacteria, and to penetrate tissues and granulomas
to allow a reduced treatment duration [4].* Correspondence: jiangxingao@163.com
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unless otherwise stated.The human immune system and classical antibacterial
agents have the capacity to destroy Mtb in the proliferat-
ing state but not in the nonreplicating “drug tolerant” or
“phenotypically drug resistant” state [5-7]. If the human
immune system is compromised or medication is stopped,
nonreplicating state Mtb quickly begin replicating [8]. The
requirement for chemotherapy is prolonged for nonrepli-
cating Mtb, which represents a major obstacle to the con-
trol of TB [9,10]. Therefore, there is an urgent need to
develop new drugs against nonreplicating Mtb to shorten
the period of Mtb chemotherapy and to decrease the
chances of treatment failure, Mtb relapse and the emer-
gence of multidrug-resistant (MDR) strains [11,12].
Mycobacteria are the only known bacterial pathogens
with proteasomes are mycobacteria [13-15], which areLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of nitroxidative stress in vitro and maintenance of the
nonreplicating state in vivo [16,17]. Therefore, the Mtb
proteasome may be required for virulence by mediating
resistance to damage by reactive oxygen and nitrogen in-
termediates (ROI/RNI), and the acidic environment of
the macrophage [18]. The Mtb proteasome removes pro-
teins damaged by ROI or RNI, and shear detoxificationTable 1 Mtb proteasome inhibitory activities of 100 natural p
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bold texts in the table. The concentration of natural products was 200 μM with the
experiments.proteins (such as repressors of genes that synthesize
DNA repair enzymes). It also degrades transcription fac-
tors that regulate the expression of genes that counteract
these host defenses [19,20]. The Mtb proteasome has
been established as a viable target for the development
of anti-TB agents and proteasome inhibitors are impli-
cated as potential drug candidates for the treatment of
nonreplicating Mtb [21,22]. In the current study, 100roducts and chemical categories
IA Name IA Name IA
41.75% ginkgolide 39.90% curcumol 34.66%
32.15% alantolactone 32.12% evodine 31.77%
23.59% bilobalide 18.56% swertiamain 14.39%
6.52% ginsenoside 2.62% limonin 1.61%
0.00% madecassoside 0.00% andrographolide 0.00%
0.00% gentiopicroside 0.00% tubeimoside A 0.00%
0.00% paclitaxel 0.00%
84.50% baicalein# 84.03% isoliquiritigenin# 83.60%




48.01% genistein 45.74% epigallocatechin gallate 45.21%
20.02% paeoniflorin 3.05% tectoridin 0.00%
0.00% silmyarin 0.00% puerarin 0.00%
0.00% diosmetin 0.00%
43.66% matrine 23.53% sophoridine 11.85%
3.67% peimine 3.05% berberine 0.00%
0.00% hanfangchin A 0.00% camptothecin 0.00%
0.00%
0.00% praeruptorin A 0.00% umbelliferone 0.00%
0.00% fraxin 0.00% osthole 0.00%




34.04% paeonol 0.00% resveratrol 0.00%





ore than 65%. Different categories of natural products were highlighted using
exception of MG132 (100 μM). Data are shown as mean of three independent
Figure 1 Mtb proteasome inhibitory activities of 12 natural
products (200 μM). The inhibitory activities of 12 natural products
(200 μM) were: hispidulin 82.06%, baicalein 84.30%, pectolinarin
88.69%, myricetin 84.50%, quercetin 74.40%, kaempferol 68.29%,
isoliquiritigenin 83.60%, icariin 74.30%, baicalin 78.47%, curcumin
69.53%, celastrol 69.50% and emodin 73.09%, the inhibitory activity
of MG132 (100 μM) is 79.66%. Data are shown as mean ± SD of
three independent experiments.
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inhibitory activity against the Mtb proteasome.
Methods
Plant-derived natural products and Mtb strain
One hundred natural products purified from plants were
purchased from Shanghai Tauto Biotech (China) with pur-
ity >98% by HPLC. Suc-LLVY-7-amido-4-methylcoumarin
(Suc-LLVY-AMC) was purchased from Boston Biochem
(Cambridge, MA, USA). Stock solutions were prepared in
DMSO.
Mtb H37Ra was cultivated on Middlebrook 7H9 medium
(0.2% glycerol, 0.5% BSA, 0.2% dextrose, 0.085% NaCl and
0.05% Tween 80; pH 6.6) or on Middlebrook 7H11 plates.
Screening of 100 natural products
Screening methods were performed as described previ-
ously with minor modifications [17,23]. Mtb H37Ra mid-
log phase (OD580 1.0) cultures were centrifuged and the
cell pellets were washed twice in phosphate buffered saline
(PBS). The cell suspension was sonicated in a lysis buffer
(50 mM Tris–HCl, pH 7.6, 50 mM NaCl, 5 mM MgCl2,
0.05% Triton X-100, 1 mM DTT and 0.5 mM EDTA).
Lysates were centrifuged at 16,000 × g for 10 minutes
and the supernatants were removed. The protein con-
centration of the supernatants was estimated with the
Bradford assay. Proteasome activity of the supernatants
was assessed. MG132 (a well-known proteasome inhibitor)
was tested as a positive control. Reaction buffer containing
substrate was added. Final concentrations were as follows:
MG132 100 μM; test natural product 200 μM; Suc-LLVY-
AMC 64 μM; protein concentration of Mtb lysates (super-
natant) 25 μg/ml, HEPES 20 mM; EDTA 0.5 mM; SDS
0.34 mg/ml; pH 7.5. Each sample was tested in three dupli-
cates. Plates were placed on an orbital shaker in an incuba-
tor at 37°C for 30 min and the fluorescence intensity of
the free AMC was recorded using a luminescence micro-
plate reader (Synergy-2, BioTek, USA) at excitation and
emission wavelengths of 360 nm and 460 nm, respectively.
IC50 assay
One hundred natural products were screened to identify
those with an inhibitory activity exceeding 65%. The in-
hibitory activity was calculated as the concentration of
inhibitor resulting in a percentage of reduction in fluor-
escent units (FU) compared to that of the control. The
fluorescence intensity of the chosen products was ana-
lyzed using the above method with a series of different
concentrations (400 μM, 200 μM, 100 μM, 50 μM,
25 μM, 12.5 μM and 6.25 μM) and the corresponding
inhibition activities were calculated. The IC50 values of
natural products with good inhibitory activities were cal-
culated by dose response curve. The IC50 values werecalculated by fitting with the four parameter logistic
(4-PL) model, y = A2 + (A1-A2)/(1 + (×/IC50)^p), with
OriginPro 8.1 (OriginLab, Inc.), where y is percent in-
hibition, x is inhibitor concentration, p is the slope of
the concentration–response curve, A1 is the minimal
inhibition ratio from three independent assays, and A2
is the maximal inhibition ratio from three independent
assays.Results
Inhibitory activities of 100 natural products
The one hundred selected natural products represent 12
categories including terpanoid (27), flavonoid (27), alkaloid
(14), coumarin (8), quinone (6), phenol (5), organic acid
(4), lignan (3), nucleoside (1), glycoside (2), steroid sapoge-
nin (2), and stilbene (1).
The Mtb proteasome inhibitory activity of MG132 was
79.66% at 100 μM, and the proteasome inhibitory activ-
ities of 12 of the 100 natural products (at 200 μM) were
more than 65%. Specifically, these 12 products were his-
pidulin, baicalein, pectolinarin, myricetin, quercetin, curcu-
min, kaempferol, isoliquiritigenin, icariin, baicalin, celastrol
and emodin (Table 1 and Figure 1). In addition to emodin
(quinones) and tripterine (terpenoids), the remaining 10
natural products belonged to the flavonoids group.IC50 values of 12 natural products against the Mtb
proteasome
Twelve natural products showed concentration-dependent
proteasomal inhibitory activities. IC50 values were calcu-
lated by fitting with the four parameter logistic (4-PL)
model (Figures 2, 3 and Table 2) and the minimal IC50 of
the 12 natural products was 45.65 μM.
Figure 2 Dose response curves of inhibitory activities of MG132, baicalein, pectolinarin, myricetin, hispidulin, isoliquiritigenin and
quercetin. The IC50 values were calculated by fitting with the four parameter logistic (4-PL) model: A. MG132 IC50=27.97 μM, R2=0.99. B. baicalein
IC50=45.65 μM, R2=0.97. C. pectolinarin IC50=49.96 μM, R2=0.97. D. myricetin IC50=55.39 μM, R2=0.96. E. hispidulin IC50=58.31 μM, R2=0.97.
F. isoliquiritigenin IC50=63.90 μM, R2=0.99. G. quercetin IC50=71.29 μM, R2=0.96. R2, adjust R square values. Dose response curves of inhibitory
activity were presented. Data are shown as mean ± SD of three independent experiments.
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Natural products, as similar as secondary metabolites, ex-
hibit diversity in structures and biological activities. These
compounds play an important role in the discovery of lead
compounds and more than 50% of FDA-approved drugs
are either natural products or natural product derivatives
[24,25]. Furthermore, natural products have specific select-
ivity for cellular targets [26], with biologically active natural
products providing selective ligands for disease-related tar-
gets [27]. The in vitro inhibitory activity of crude extractsand/or pure active compounds extracted from plants
against Mtb has been extensively reported [28-31].
Twelve of the 100 natural products selected for inves-
tigation in this study exhibited inhibitory activities
against the proteasome exceeding 65%. Among these, 10
natural products were flavonoids. Thus, in our study, fla-
vonoids showed better inhibitory activities against the
Mtb proteasome than other categories, implicating flavo-
noids as potential proteasome inhibitors. Although some
flavonoids showed inhibitory activities against the Mtb
Figure 3 Dose response curves of inhibitory activities of emodin, baicalin, icariin, kaempferol, celastrol and curcumin. The IC50 values
were calculated by fitting with the four parameter logistic (4-PL) model: A. emodin IC50=81.05 μM, R2=0.97. B. baicalin IC50=83.52 μM, R2=0.99.
C. icariin IC50=88.67 μM, R
2=0.99. D. kaempferol IC50=106.74 μM, R
2=0.99. E. celastrol IC50=114.02 μM, R
2=0.98. F. curcumin IC50=114.27 μM,
R2=0.99. R2, adjust R square values. Dose response curves of inhibitory activity were presented. Data are shown as mean ± SD of three
independent experiments.
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relatively higher than that of the positive control
(MG132, 27.97 μM). Our study provides an insight into
the unique features of potential proteasome inhibitors.
Natural flavonoids, which exist widely in nature, are sec-
ondary metabolites of plants and perform a wide range ofTable 2 IC50 of 12 natural products
Natural products IC50 (μM) Natural products IC50 (μM)
baicalein 45.65 emodin 81.05
pectolinarin 49.96 icariin 88.67
quercetin 71.29 kaempfero 106.74
hispidulin 58.31 baicalin 83.52
myricetin 55.39 celastrol 114.02
isoliquiritigenin 63.90 curcumin 114.27
MG 132(control) 27.97
The IC50 values of 12 natural products were calculated by dose response curve.functions. The chemical structure of flavonoids is based
on a fifteen-carbon skeleton consisting of two benzene
rings (A and B) linked by a heterocyclic pyrane ring (C),
showing a common three ring structure (C6–C3–C6)
(Figure 4) [32]. In this study, despite the finding thatFigure 4 Basic structures of flavonoids.
Figure 5 Six natural products of the flavonoids with good inhibitory activity on the Mtb proteasome. Inhibitory activities of six flavonoids
(each 200 μM) were as follows: baicalein 84.30%, pectolinarin 88.69%, hispidulin 82.06%, myricetin 84.50%, quercetin 74.40% and kaempferol
68.29%. The common structural features are the hydroxyl at the C ring C-3 (myricetin, quercetin and kaempferol), or the hydroxyl (baicalein) or
the methoxyl (pectolinarin and hispidulin) at the A ring C-6.
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proteasome was better than that of other categories,
there was a wide variation in the inhibitory activities be-
tween different flavonoid products. The structures of
flavonoids with good inhibitory activity were shown in
Figure 5 and those with little inhibitory activity were
shown in Figure 6. The common structures of the flavo-
noids with effective inhibitory activity against the Mtb
proteasome are hydroxyl residue at the C ring C-3, or
hydroxyl/methoxyl residue at the A ring C-6. This indi-
cates some key functional structures of flavonoids with
inhibitory activity against the Mtb proteasome.
The well-established free-radical scavenging ability of
flavonoids depends on electron-donating hydroxyl group
substitutions of the aromatic A ring and the heterocyclic
C ring [33]. The C-2–C-3 double-bond conjugated to aFigure 6 Six natural products of the flavonoids with little inhibitory a
(at 200 μM) were zero. Compared with Figure 5, these compounds are with
the A ring C-6.C-4 carbonyl group on the C ring is responsible for anti-
oxidant activity [23]. Comprehensive analysis of the cor-
relations between functional groups in the flavonoid
structures and their proteasome inhibitory activities are
necessary to evaluate the effects of modifications at the
C ring C-3 and the A ring C-6.Conclusions
The flavonoid structure has been shown to be a viable
template for the design of potent Mtb proteasome inhib-
itors. This information forms the basis of the rational
design of flavonoid analogs retaining the key functional
groups, which will focus direct screening and will be
helpful to accelerate the discovery of potent inhibitors of
the Mtb proteasome.ctivity on the Mtb proteasome. Inhibitory activities of six flavonoids
out the hydroxyl at the C ring C-3 and the hydroxyl or methoxyl at
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